No impact of cancer and plague-relevant


Journal

Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
08 12 2020
Historique:
entrez: 21 12 2020
pubmed: 22 12 2020
medline: 8 1 2021
Statut: epublish

Résumé

Formyl peptide receptor 1 (FPR1) is a pattern-recognition receptor that detects bacterial as well as endogenous danger-associated molecular patterns to trigger innate immune responses by myeloid cells. A single nucleotide polymorphism, rs867228 (allelic frequency 19-20%), in the gene coding for FPR1 accelerates the manifestation of multiple carcinomas, likely due to reduced anticancer immunosurveillance secondary to a defect in antigen presentation by dendritic cells. Another polymorphism in

Identifiants

pubmed: 33344044
doi: 10.1080/2162402X.2020.1857112
pii: 1857112
pmc: PMC7734042
doi:

Substances chimiques

FPR1 protein, human 0
Receptors, Formyl Peptide 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1857112

Informations de copyright

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Références

Front Immunol. 2015 Aug 18;6:422
pubmed: 26347745
Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L775-L786
pubmed: 30188748
Sci Rep. 2012;2:786
pubmed: 23139859
Cancer Discov. 2020 Oct 12;:
pubmed: 33046534
J Immunol. 2007 Apr 1;178(7):4595-605
pubmed: 17372018
Cancer Res. 2016 Jun 1;76(11):3122-6
pubmed: 27197163
PLoS Comput Biol. 2018 Mar 21;14(3):e1006069
pubmed: 29561846
Genes Immun. 2001 Oct;2(6):335-42
pubmed: 11607790
BMC Med. 2020 Jul 15;18(1):216
pubmed: 32664879
Am J Respir Crit Care Med. 1994 Feb;149(2 Pt 1):464-8
pubmed: 8306047
Clin Exp Immunol. 2015 May;180(2):165-77
pubmed: 25560985
Pharmacol Ther. 2010 Oct;128(1):119-28
pubmed: 20599443
Mol Cell. 2000 May;5(5):831-40
pubmed: 10882119
Science. 2015 Nov 20;350(6263):972-8
pubmed: 26516201
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Trends Pharmacol Sci. 2003 Nov;24(11):574-9
pubmed: 14607080
Nat Rev Immunol. 2020 Feb;20(2):95-112
pubmed: 31558839
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Oncoimmunology. 2016 Feb 18;5(6):e1139275
pubmed: 27471610
Oncoimmunology. 2020 Aug 25;9(1):1807836
pubmed: 32939324
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
J Immunol. 2020 May 1;204(9):2464-2473
pubmed: 32221037
Trends Mol Med. 2019 Apr;25(4):315-327
pubmed: 30871809
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Oncoimmunology. 2020 Apr 30;9(1):1760061
pubmed: 32391192
Transl Res. 2018 Dec;202:52-68
pubmed: 30165038
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
PLoS One. 2015 Sep 17;10(9):e0138338
pubmed: 26378785
Cell Stress. 2020 Mar 02;4(4):66-75
pubmed: 32292881
Nature. 2019 Oct;574(7776):57-62
pubmed: 31534221
Am J Respir Cell Mol Biol. 2012 Sep;47(3):332-9
pubmed: 22461430
J Immunol. 2004 Jun 15;172(12):7669-76
pubmed: 15187149
JCI Insight. 2020 Feb 27;5(4):
pubmed: 32102985
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Cell Death Differ. 1997 Aug;4(6):443-56
pubmed: 16465265
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Cell Stress. 2019 May 23;3(6):195-207
pubmed: 31225514
Genome Biol. 2017 Apr 27;18(1):76
pubmed: 28449694
J Innate Immun. 2014;6(1):111-6
pubmed: 23860188
Am J Pathol. 2015 May;185(5):1172-84
pubmed: 25791526
Lancet Infect Dis. 2020 Sep;20(9):e238-e244
pubmed: 32628905
Immunol Rev. 2020 Jul;296(1):205-219
pubmed: 32658335
Exp Cell Res. 2018 Sep 15;370(2):506-518
pubmed: 30031130

Auteurs

Adriana Petrazzuolo (A)

Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
Faculty of Medicine Kremlin Bicêtre, Université Paris Saclay, Paris, France.

Julie Le Naour (J)

Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
Faculty of Medicine Kremlin Bicêtre, Université Paris Saclay, Paris, France.

Erika Vacchelli (E)

Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.

Pascale Gaussem (P)

Hematology Department and Biosurgical Research Lab, (Carpentier Foundation) Assistance Publique Hôpitaux De Paris-Centre Université De Paris (APHP-CUP), Paris, France.
Innovative Therapies in Haemostasis, INSERM, Université De Paris, Paris, France.

Syrine Ellouze (S)

Biological Hematology Department, Assistance Publique-Hôpitaux De Paris. Centre-Université De Paris, Paris, France.

Georges Jourdi (G)

Innovative Therapies in Haemostasis, INSERM, Université De Paris, Paris, France.
Biological Hematology Department, Assistance Publique-Hôpitaux De Paris. Centre-Université De Paris, Paris, France.

Eric Solary (E)

Faculty of Medicine Kremlin Bicêtre, Université Paris Saclay, Paris, France.
INSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France.

Michaela Fontenay (M)

Biological Hematology Department, Assistance Publique-Hôpitaux De Paris. Centre-Université De Paris, Paris, France.
Institut Cochin, CNRS UMR8104, INSERM U1016, Université De Paris, Paris, France.

David M Smadja (DM)

Hematology Department and Biosurgical Research Lab, (Carpentier Foundation) Assistance Publique Hôpitaux De Paris-Centre Université De Paris (APHP-CUP), Paris, France.
Innovative Therapies in Haemostasis, INSERM, Université De Paris, Paris, France.

Guido Kroemer (G)

Equipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
Institut Universitaire De France, Paris, France.
AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.
Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH